Beyond Biotech - the podcast from Labiotech
Welcome to the official Labiotech.eu podcast - Beyond Biotech! Each week, we talk about what's happening in the world of biotech, with news and interviews with experts from companies around the world. Join us as we cover the latest news, breakthroughs and innovations shaping the life sciences industry.A new podcast episode is available every Friday.The host is Jim Cornall.
Episodes
123 episodes
Beyond profits: The Bill & Melinda Gates MRI's mission to combat neglected diseases
The Bill & Melinda Gates Medical Research Institute (Gates MRI) is a non-profit medical research organization dedicated to the development and effective use of products like drugs, vaccines and monoclonal antibodies to address substantia...
•
38:10
How to succeed as a woman in biotech
This week, we are taking a look at an important subject, and that is women working as CEOs, or other senior roles, in the biotech space. Kate Yen is the CEO of oncology biotech Auron Therapeutics, and she has spent her entire...
•
34:12
The immunometabolism landscape
Sitryx Therapeutics is a private UK biopharma company founded in 2018. It is a leader in the field of immunometabolism, an area of immunology that looks to rebalance the immune system to achieve sustained disease remission in autoimmune and ...
•
30:13
Biotech beyond earth: The future of medicine in space
LinkGevity, founded by two sisters, is developing anti-necrotic technologies, especially for application in kidney disease.Carina Kern is the CEO of the company, while Serena Kern-Libera is the chief operating officer. After reading an a...
•
39:01
The future of gene therapy
Today, gene therapy is at an exciting inflection point as the industry moves beyond the first generation of these therapies. However, challenges and barriers remain in bringing gene therapies to market, particularly as they expand into more ...
•
33:25
Bispecific ADCs: the next generation of cancer treatments
Antibody-drug conjugates have been an area of great interest in the oncology space in recent years, with a record rate of FDA approvals and dealmaking activity. However balancing efficacy and off-site toxicity has remained a challenge.
•
29:45
Targeting telomerase to disrupt cancer
Telomeres are structures made from DNA sequences and proteins, and they are found at the ends of chromosomes. In effect, they cap and protect the end of a chromosome. Telomerase is an enzyme that adds DNA to the ends of chromosom...
•
26:30
Harnessing the body’s natural targeted protein degradation system to treat diseases
C4 Therapeutics (C4T) is a leader in the targeted protein degradation (TPD) field, with two oncology drug candidates currently in clinical trials and collaborations with pharma companies like Merck, Biogen and Roche. The clinical-st...
•
34:04
Estonia's biobank: Is this the first large-scale personalized medicine initiative?
Estonia is working on becoming the first country to implement personalized health at scale through the Estonian National Biobank.The biobank uses genetic data to create a picture of the Estonian population, leading to the potential adapt...
•
32:15
Targeting inflammation: A revolution in disease treatment
Inflammation appears to affect almost every part of the human body as we age, including cancer, type-2 diabetes, obesity, and neurodegenerative disorders.NLRP3 inflammasome-induced inflammation is at the root of nearly all disease...
•
43:10
The power of tumor infiltrating lymphocytes to fight melanoma
Tumor infiltrating lymphocyte (TIL) therapy uses a person’s own immune cells to fight advanced melanoma, offering new hope for patients who have limited treatment options. This week, we have a conversation with Brian Gastman,...
•
38:03
The future of combination vaccines
The development of combination vaccines could represent a significant advancement in the fight against infectious diseases. With the potential to streamline the vaccination process and provide broader protection, these vaccines could greatly im...
•
24:44
New German biotech spins out to develop radiotherapeutics
Pentixapharm is a clinical-stage radiopharmaceutical development company targeting a range of diseases. While it is currently owned by the Eckert & Ziegler Group, it will soon be spun off as a separate company. Pentixapharm’s cl...
•
18:35
Challenging the European biotech funding status quo
There are many questions when it comes to setting up a biotech company, and raising funds. Currently, many companies are concerned about fundraising, but there are things that can be done to maximize efforts. Does a company’s loc...
•
36:36
[Rebroadcast] Epigenetic editing – the power of CRISPR without cutting DNA
While our podcast takes a brief break, Labiotech invites you to enjoy some of our favorite episodes. We will return with a brand-new episode on August 16, 2024! Have an awesome summer!Epic Bio is an epigenetic editing company, levera...
•
32:57
[Rebroadcast] How does AI assist drug discovery?
While our podcast takes a brief break, Labiotech invites you to enjoy some of our favorite episodes. We will return with a brand-new episode on August 16, 2024! Have an awesome summer!Artificial intelligence (AI) is certainly in the ...
•
38:40
The first mass-market cell therapy?
Aurion Biotech is a US biotech with a regenerative medicine platform, developing novel therapies to restore vision to millions of people in need. This week on the podcast, we have a conversation with CEO Greg Kunst about Auri...
•
25:34
Cutting through the AI hype in drug discovery
LabGenius is a drug discovery company developing next-generation therapeutic antibodies. The company’s discovery platform, EVA, integrates several technologies drawn from the fields of artificial intelligence (AI), robotic a...
•
26:13
How biotechs are revolutionizing acute on-chronic liver failure?
Acute on-chronic liver failure (ACLF) is a significant healthcare issue with high unmet needs for patients and clinicians, and a massive burden for healthcare systems. It cost more than $6bn in the US alone in 2021, with a drastic increase o...
•
29:22
The radiotherapeutics boom
The field of radiotherapeutics is a hot topic currently, and so who better to talk about the subject than Ken Herrmann, a radiopharmaceutical academic expert, who is Professor of Nuclear Medicine at the Universitätsklinikum Essen, in Essen Germ...
•
39:43
Priovant - finding options to treat autoimmune diseases
US-based biotech company Priovant Therapeutics is dedicated to developing novel therapies for autoimmune diseases with high morbidity and few available treatment options. The company's lead asset, brepocitinib, is a dual sele...
•
30:05
How ADCs can deliver death cap mushroom toxins to treat cancer
Heidelberg Pharma is a clinical stage biotech company developing antibody drug conjugates (ADCs).Its lead amanitin-based ADC product candidate, HDP-101, targets relapsed or refractory multiple myeloma. HDP-101 recently received or...
•
28:09
Looking to cure Type 1 diabetes
Diamyd Medical develops precision medicine therapies for the prevention and treatment of Type 1 diabetes and LADA (latent autoimmune diabetes in adults). Diamyd is an antigen-specific immunomodulatory therapeutic for the pres...
•
23:40